Equities research analysts predict that INmune Bio Inc (NASDAQ:INMB) will post earnings of ($0.19) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for INmune Bio’s earnings. The company is scheduled to announce its next earnings results on Monday, January 1st.
On average, analysts expect that INmune Bio will report full year earnings of ($0.76) per share for the current financial year. For the next year, analysts expect that the company will post earnings of ($0.75) per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that cover INmune Bio.
Separately, Maxim Group assumed coverage on shares of INmune Bio in a report on Tuesday, March 19th. They issued a “buy” rating and a $13.00 price target on the stock.
INmune Bio Company Profile
INmune Bio Inc, a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood.
Featured Article: What are economic reports?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.